

Title (en)  
METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES

Title (de)  
VERFAHREN ZUR ELIMINIERUNG VON HÄMATOPOETISCHEN STAMMZELLEN/HÄMATOPOETISCHEN VORLÄUFERZELLEN (HSC/HP) IN EINEM PATIENTEN MIT BI-SPEZIFISCHEN ANTIKÖRPERN

Title (fr)  
PROCÉDÉ D'ÉLIMINATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUE/PROGÉNITEURS HÉMATOPOÏÉTIQUES (CSH/PH) CHEZ UN PATIENT À L'AIDE D'ANTICORPS BISPÉCIFIQUES

Publication  
**EP 3997128 A1 20220518 (EN)**

Application  
**EP 20836912 A 20200708**

Priority  
• US 201916506764 A 20190709  
• US 2020041095 W 20200708

Abstract (en)  
[origin: WO2021007266A1] The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.

IPC 8 full level  
**C07K 16/28** (2006.01); **A61K 39/395** (2006.01); **A61K 45/06** (2006.01)

CPC (source: EP)  
**A61P 37/06** (2017.12); **C07K 16/2809** (2013.01); **C07K 16/2863** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/55** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/77** (2013.01); **C07K 2317/92** (2013.01)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2021007266 A1 20210114**; CA 3146912 A1 20210114; CN 114829399 A 20220729; EP 3997128 A1 20220518; EP 3997128 A4 20231018; JP 2022540602 A 20220916

DOCDB simple family (application)  
**US 2020041095 W 20200708**; CA 3146912 A 20200708; CN 202080062829 A 20200708; EP 20836912 A 20200708; JP 2022501020 A 20200708